or
Remember me
NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.
Back
A daily snapshot of everything from market open to close.
NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).
In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.
The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.
Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu